Table 4. Multivariate survival analyses for HER2-positive primary breast cancer patients treated with adjuvant trastuzumab in the second set.
|
Multivariate analysis |
|||||
|---|---|---|---|---|---|
| Model | Variable | Category | HR | 95% CI | P-value |
|
Disease-free survival | |||||
| 1 | EGFR overexpression (3+) | Positive vs negative | 2.837 | 1.172–6.863 | 0.021 |
| pT stage | T2–T3 vs T1 | 2.000 | 0.928–4.310 | 0.077 | |
| pN stage | N1–N3 vs N0 | 1.608 | 0.637–4.063 | 0.315 | |
| Lymphovascular invasion | Positive vs negative | 2.368 | 1.113–5.038 | 0.025 | |
| 2 | EGFR overexpression (2+ or more) | Positive vs negative | 3.177 | 1.587–6.359 | 0.001 |
| pT stage | T2–T3 vs T1 | 2.106 | 0.980–4.522 | 0.056 | |
| pN stage | N1–N3 vs N0 | 1.673 | 0.667–4.196 | 0.273 | |
| Lymphovascular invasion | Positive vs negative | 2.487 | 1.175–5.264 | 0.017 | |
|
Overall survival | |||||
| 1 | EGFR overexpression (3+) | Positive vs negative | 4.697 | 1.958–11.266 | 0.001 |
| pT stage | T2–T3 vs T1 | 2.640 | 0.987–7.061 | 0.053 | |
| Lymphovascular invasion | Positive vs negative | 2.870 | 1.190–6.924 | 0.019 | |
| 2 | EGFR overexpression (2+ or more) | Positive vs negative | 4.582 | 2.075–10.119 | <0.001 |
| pT stage | T2–T3 vs T1 | 2.808 | 1.051–7.498 | 0.039 | |
| Lymphovascular invasion | Positive vs negative | 3.143 | 1.303–7.582 | 0.011 | |
Abbreviations: CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio.